Thank you for attending today's DT & IT Pharma Townhall! In today's meeting, we delved deeper into the successful launch of the Pharma Control Tower (go/PHCT), which serves as a central entry point for all your needs related to financial, operational stability, and governance for your applications, portfolios, and functions. Additionally, we shared some updates on the rollout of MyGenAssist at Pharma, highlighting our crucial role as key ambassadors. This past year has underscored the accelerated pace of innovation, with GenAI standing out as a prime example of the agility needed to proactively evolve our skill sets. Furthermore, we collectively reviewed our key priorities for 2024 and provided updates on our DSO learning journey. In summary: ///// PH Control Tower ///// Business priorities per department ///// MyGenAssist roll-out PH ///// DSO Champions update Bayer terms & conditions apply: https://www.bayer.com/en/poap-tc

Another DSO Open MIC session is in the books! Whether you have attended the morning or afternoon session, without a doubt you have contributed significantly to the success of today's event. These sessions are a space for open exchanges about ongoing topics around DSO and an opportunity to share, ask questions, provide feedback, or just listen. Everyone is invited to attend, participation is voluntary, and the sessions will not be recorded. Bayer terms & conditions apply: https://www.bayer.com/en/poap-tc

Rare diseases are defined by their low prevalence in the population, leading to challenges in diagnosis, research, and treatment. Definitions vary; in the US, a disease is rare if it affects fewer than 1:1,500 individuals, Europe 1:2,000, Japan 1:2,500. There are some 7,000 rare diseases, impacting around 6-8% of the world at some point, some 300 million currently. They are incredibly diverse, ranging from genetic disorders to rare cancers, and can be chronic, progressive, debilitating, and often life-threatening. Some well-known rare diseases include cystic fibrosis, Duchenne muscular dystrophy, and Huntington's disease, each with their own unique symptoms, treatment challenges, and research needs. Rare diseases are closely related to orphan diseases, a term that originally referred to diseases neglected by drug developers due to the small market potential. However, the terms are now often used interchangeably. Legislation such as the Orphan Drug Act of 1983 in the U.S. has incentivized pharmaceutical companies to develop treatments for rare (orphan) diseases, offering benefits like tax credits and exclusive marketing rights. The rarity and diversity of these diseases pose significant hurdles for research and clinical trials, Raising awareness and support for those affected are crucial for research funding to develop diagnostics, treatments, and hopefully cures. https://en.wikipedia.org/wiki/Rare_disease Art+Text supported by ChatGPT